Immunological changes after ASIT in AD allergen-specific immunotherapy and their potential correlation with clinical response in patients with atopic dermatitis patients sensitized to house dust mite

Background. Allergen-specific immunotherapy (SIT) is one of the important regimens for the treatment of allergic diseases. Predictive tests for the clinical response to SIT are limited. In this study we aimed to evaluate whether specific IgE/total IgE levels can predict clinical improvement in monosensitized patients to house dust mite treated with immunotherapy. Patients and Methods. We analyzed 32 patients who had undergone 2 years of SIT. Serum t-IgE and s-IgE levels, and serum s-IgE/t-IgE ratios were calculated and tested for correlation with clinical response to SIT. Asthma symptom score (ASS), rhinitis symptom score (RSS), pulmonary functions and visual analogue scales (VAS) were evaluated at the beginning and after 2 years. Results. There were 17 boys and 15 girls with the mean age of 10.78±3.03 years. The mean serum house dust mite s-IgE level was 128.62±142.61 kU/L, t-IgE 608.90±529.98 IU/mL, and s-IgE/t-IgE ratio 33.83±53.18. Before immunotherapy, ASS was 6.23±1.63, RSS; 8.20±1.88, VAS; 7.38±2.01, FEV1 (%); 89.14±8.48, PEF (%); 88.93±13.57, and after 2 years, these values were determined as 1.90±1.10, 3.05±1.39, 1.35±1.24, 97.6±11.26, and 97.0±11.55, respectively. s-IgE/t-IgE ratio was correlated with change in RSS (r=−0.392, P=0.08) and VAS (r=−0.367, P=0.05). Conclusion. Although SIT is very effective treatment, all patients do not benefit from treatment. We assumed that s-IgE/t-IgE ratio would be useful to predict the clinical response to SIT.

Download Full-text

Design of a pivotal phase III trial of allergen specific immunotherapy (AIT) using a high-dose house dust mite (HDM) allergoid in patients with allergic bronchial asthma

10.26226/morressier.5acc8ad4d462b8028d89b144 ◽

2018 ◽

Author(s):

Michael Rudert ◽

Viola Gödicke

Keyword(s):

Bronchial Asthma ◽

House Dust ◽

House Dust Mite ◽

Specific Immunotherapy ◽

Phase Iii ◽

High Dose ◽

Pivotal Phase ◽

Allergen Specific Immunotherapy ◽

Phase Iii Trial ◽

Dust Mite

Download Full-text

Allergen‐specific immunotherapy boosts allergen‐specific IgD production in house dust mite‐sensitized asthmatic patients

Allergy ◽

10.1111/all.14133 ◽

2020 ◽

Vol 75 (6) ◽

pp. 1457-1460 ◽

Cited By ~ 5

Author(s):

Tadech Boonpiyathad ◽

Panitan Pradubpongsa ◽

Wat Mitthamsiri ◽

Pattraporn Satitsuksanoa ◽

Alain Jacquet ◽

...

Keyword(s):

House Dust ◽

House Dust Mite ◽

Specific Immunotherapy ◽

Allergen Specific Immunotherapy ◽

Asthmatic Patients ◽

Dust Mite

Download Full-text

Long-term effects of allergen-specific subcutaneous immunotherapy for house dust mite induced allergic rhinitis

The Journal of Laryngology & Otology ◽

10.1017/s0022215117002110 ◽

2017 ◽

Vol 131 (11) ◽

pp. 997-1001 ◽

Cited By ~ 5

Author(s):

E Sahin ◽

D Dizdar ◽

M E Dinc ◽

A A Cirik

Keyword(s):

Allergic Rhinitis ◽

House Dust ◽

House Dust Mite ◽

Specific Immunotherapy ◽

Subcutaneous Immunotherapy ◽

Long Term Effects ◽

Allergen Specific Immunotherapy ◽

Dust Mite ◽

Symptom Scores

AbstractBackground:Allergic rhinitis is strongly associated with the presence of house dust mites. This study investigated the long-term effects of allergen-specific immunotherapy. Allergen-specific immunotherapy was applied over three years. The study was based on a 10-year follow up of patients with allergic rhinitis.Methods:The study was conducted between 2001 and 2015. Skin prick test results and symptom scores were evaluated before (26 patients) and after 3 years (20 patients) of allergen-specific immunotherapy (using data from a previously published study), and 10 years after allergen-specific immunotherapy had ended (20 of 26 patients).Results:The symptom scores before allergen-specific immunotherapy were significantly higher than those obtained after 3 years of allergen-specific immunotherapy and 10 years after allergen-specific immunotherapy (p < 0.0175). There were no significant differences between the scores obtained at 3 years and 10 years after allergen-specific immunotherapy (p > 0.0175).Conclusion:Subcutaneous immunotherapy is an effective treatment for house dust mite induced allergic rhinitis.

Download Full-text